The field of lung cancer is always changing. With each passing year, the number of agents, lines of therapy, and targets for treatment grows. This year was no different.
2018 saw the approval of or expanded indication for the EGFR inhibitors afatinib, dacomitinib, and osimertinib, checkpoint inhibitors atezolizumab, durvalumab, nivolumab, and pembrolizumab, and the ALK inhibitor lorlatinib—to name a few.
Whether the change is to frontline treatment, metastatic disease, squamous or non-squamous non-small cell lung cancer (NSCLC), or small cell disease, every advancement made is an exciting time for our patients and another reminder of the importance of continued education.
With new approvals comes a multitude of data to decipher, recommendations to incorporate, practice changes to make, and patients to consider. Now, as the new year approaches it’s time again for the Winter Lung Cancer Conference™. It’s time to gather once again, review everything that’s changed in 2018, and prepare for all the changes to come in 2019.
I can’t wait to see you in Miami!
Heather A. Wakelee, MD